+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 99Years
MALE
ID05915442

Phase 2 Study of SBRT with Zimberelimab, Etrumadenant, and Quemliclustat for Men with Hormone Sensitive Oligometastatic Prostate Cancer

Led by Catherine Spina · Updated on 2025-05-20

23

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a combination of drugszimberelimab, etrumadenant, and quemliclustatalongside metastasis-directed stereotactic body radiation therapy SBRT in men with hormone-sensitive oligometastatic prostate cancer. The study aims to test whether targeting the adenosine signaling pathway and immune checkpoint inhibition with these drugs plus SBRT will improve local control, progression-free survival, and hormone therapy-free survival compared to SBRT alone. This is a Phase II study focused on overcoming immune suppression in the tumor environment to improve treatment outcomes.

CONDITIONS

Brief Title

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Research Team

C

Catherine S. Spina, MD, PhD

R

Research Nurse Navigator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here